Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

  • 183 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
183
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Prevention and Treatment of Prostate Cancer: Technologies andGlobal MarketsReport Details:Published:January 2013No. of Pages: 235Price: Single User License – US$5450REPORT HIGHLIGHTSThis report provide:•An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents•Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017•Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer•Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening•Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents•Evaluation of prostate cancer treatment products by geography, race, and category•Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand•Comprehensive company profiles.STUDY GOALS AND OBJECTIVESThis report “Prevention and Treatment of Prostate Cancer: Technologies and Global Markets”provides an overview of the current and potential global market for prostate cancer treatments andtesting technologies. The key objective is to present a comprehensive analysis of the current stateof prostate cancer therapy and technology, utilization of the various therapeutic and diagnosticmodalities to prevent and treat prostate cancer. The reports focus is on prostate cancer treatmentstrategies such as hormone therapy, chemotherapy, radiotherapy and immunotherapy, and othertreatment modalities and testing and screening methods. The report also includes an overview onprostate cancer staging, diagnostic strategies and technologies. Important trends in the field ofprostate cancer research and development have been reviewed in this report, and sales forecastsby treatment and screening categories are provided from 2012 through 2017. Issues and trendsaddressed in this report are based on information from industry sources, regulatory and healthcarepolicies, demographics and other factors that directly affect the prostate cancer market.
  • 2. REASONS FOR DOING THIS STUDYThis study was conducted to provide detailed information regarding screening, testing andtreatment options for prostate cancer. There is an increasing need for new and innovativetechnologies. This industry is experiencing growth. The use of new drug delivery technologies forprostate cancer has increased in the past few years. This study looks at most types of treatmentstrategies for the clinical management of prostate cancer.This BCC market research report will increase the awareness of current and emerging drugs andtechnologies for prostate cancer, including hormone therapy, chemotherapy, radiation therapy,surgical therapy, immunotherapy and also nutrition therapy.SCOPE OF THE STUDYThe scope of this study is testing, screening technology and also therapeutics markets for prostatecancer. The report also includes the regulatory environment, current technologies, newtechnologies, prostate cancer incidence, market projections and market share, along with latesttrends and new developments.METHODOLOGYBoth primary and secondary research methodologies were used in preparing this report.Secondary sources include books, newspapers, trade journals, white papers, industry portals,government agencies, trade associations, monitoring industry news and developments, andthrough access to paid and free databases. The base year of the report is 2012, with forecast dataprovided through 2017. Historical, base year and forecast data are provided for each marketsegment of this report. The report provides a comprehensive review of prostate cancer, incidenceand development of the disease, drugs currently being used and diagnostic technologies. Thereport also reviews technological developments, product innovations/ introductions and recentstrategic industry activity of major players across various product categories. Growth rates, globalincidence and projections are determined through a compilation of data, including past trends,future trends, demographics, incidence, mortality, products in R&D and current product growth,etc. Forecasts and projections were based on estimates such as the current trends, potentialusers, mergers and acquisitions, and market trends.A comprehensive and exhaustive search of the literature on prostate cancer assay developmentand already-marketed products, global incidence and latest drug developments was conducted.These secondary sources included scientific-related journals and articles, textbooks, pressreleases, marketing literature, other product/promotional literature, annual reports, security analystreports and other publications. A patent search and analysis were also conducted. Some informalinterviews were also conducted with experts and personnel in this area at biotech andpharmaceutical companies. Other resources included academics, technology and consultingcompanies.INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. Included weremanufacturers, end users of products, which included pharmaceutical and biotechnical industries,research institutes, etc. Data were gathered from various industry sources. BCC spoke withofficials within the industry, consulted newsletters, company literature, product literature and a hostof technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by
  • 3. key terminology were completed. In addition, data were compiled from current financial, trade andgovernment sources.Get your copy of this report @http://www.reportsnreports.com/reports/213066-prevention-and-treatment-of-prostate-cancer-technologies-and-global-markets.htmlMajor points covered in Table of Contents of this report includeTABLE OF CONTENTSChapter - 1: INTRODUCTIONSTUDY GOALS AND OBJECTIVESREASONS FOR DOING THIS STUDYINTENDED AUDIENCESCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHORRELATED BCC REPORTSBCC ON-LINE SERVICESDISCLAIMERChapter - 2: SUMMARYTable Summary: GLOBAL PROSTATE CANCER MARKET, THROUGH 2017Figure Summary: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017Chapter - 3: OVERVIEWINTRODUCTIONU.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONSTable 1: U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008BIOLOGY OF PROSTATE CANCERPROSTATE GLANDPROSTATE GLAND FUNCTIONGROWTH OF THE PROSTATE GLANDTYPES OF PROSTATE CANCERPRECANCEROUS CONDITIONS OF THE PROSTATEProstatic Intraepithelial Neoplasia (PIN)Proliferative Inflammatory Atrophy (PIA)PROSTATE CANCER DEVELOPMENT AND AGINGMECHANISMS OF DISEASE DEVELOPMENT PATHOPHYSIOLOGYFAMILY HISTORYENVIRONMENTAL FACTORSEPIDEMIOLOGY AND RISK FACTORSHORMONESGROWTH FACTORSTable 2: GROWTH FACTORS IMPLICATED IN PROSTATE CANCER
  • 4. GENETICSTable 3: PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCIMOLECULAR MECHANISMS OF PROSTATE CANCERTable 4: IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCERTHE ANDROGEN RECEPTORPTENP53GSTP GENESTable 5: MUTATED GENES AND ABNORMAL PROTEIN EXPRESSIONPROSTATE-SPECIFIC ANTIGENCAVEOLIN-1EMSYAMACRKLF6NBS1CHEK2MISMATCH REPAIR GENESHOXB13BRCA1 AND BRCA2HEREDITARY PROSTATE CANCERPROSTATE CANCER PREVENTION AND TREATMENTCONCLUSIONSChapter - 4: PROSTATE CANCERDETECTION AND DIAGNOSISDIAGNOSISHow is Prostate Cancer Diagnosed?Tests to Diagnose Prostate CancerSCREENING, DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCERGUIDELINES FOR PROSTATE CANCER SCREENINGRECOMMENDATIONS FOR PROSTATE CANCER EARLY DETECTIONNEW PROSTATE CANCER SCREENING GUIDELINESRECENT DEVELOPMENTSPROSTATE CANCER SCREENINGSTAGING AND GRADING OF PROSTATE CANCERDIAGNOSTIC BIOPSYTEST FOR METASTASISNEW METHODS IN DEVELOPMENTIMAGING STRATEGIES FOR DIAGNOSIS OF PROSTATE CANCERPROSTATE CANCER PROGNOSIS AND OUTCOMES PREDICTIONSCONCLUSIONSChapter - 5: PROSTATE CANCER SCREENING AND DIAGNOSISDIAGNOSTIC PRODUCTS
  • 5. Table 13: PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGYPROSTATE CANCER SCREENING, DIAGNOSIS AND PROGNOSISPSA TESTSNew Types of PSA TestsPercent-free PSAPSA VelocityPSA DensityAge-Specific PSA RangesTHE DREPROSTATE ULTRASOUND AND BIOPSYIMAGING TECHNOLOGIES FOR PROSTATE CANCERComputerized TomographyMagnetic Resonance ImagingEndorectal MRI TechnologyMagnetic Resonance Spectroscopic ImagingProton Radiation TherapyHigh Intensity Focused UltrasoundTable 14: PROSTATE CANCER TESTSCONCLUSIONSChapter - 6: PROSTATE CANCER: THERAPEUTIC INTERVENTIONSTREATMENT PLANTREATMENT OPTIONSWatchful Waiting or Active SurveillanceTable 16: FACTORS FOR PROSTATE CANCER TREATMENT PLANNINGTable 17: GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENTSURGERYRadical ProstatectomyTable 18: TYPES OF SURGERYSECONDARY THERAPYCounseling about Postoperative Erectile DysfunctionTable 19: ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMYRADIOTHERAPYINTERSTITIAL BRACHYTHERAPY FOR LOW-RISK CANCERSTable 20: ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHYTHERAPYEXTERNAL BEAM RADIOTHERAPYTable 21: ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPYCOMBINED RADIATION THERAPYCRYOTHERAPYTable 22: ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPYHIGH-INTENSITY FOCUSED ULTRASOUNDTable 23: ADVANTAGES AND DISADVANTAGES OF ULTRASOUNDFOCAL ABLATION
  • 6. HORMONE THERAPYTable 24: HORMONE THERAPYANDROGEN DEPRIVATION, AN ADJUVANT THERAPYPost-treatment MonitoringCHEMOPREVENTION AND CHEMOTHERAPYIMMUNOTHERAPYNUTRITIONAL THERAPYERECTILE DYSFUNCTIONEMERGING THERAPIESCombination TherapyTherapeutic VaccinesNew Drugs for Hormone-Resistance Prostate CancerInhibitors of Kinase Signaling PathwaysProteasome InhibitorsAngiogenesis InhibitorsTREATMENT STRATEGIES FOR PROSTATE CANCER BY STAGETable 25: STAGE I PROSTATE CANCERTable 26: STAGE II PROSTATE CANCERTable 27: STAGE III PROSTATE CANCERTable 28: STAGE IV PROSTATE CANCERTable 15: TREATMENT OPTIONS FOR PROSTATE CANCERChapter - 7: PROSTATE CANCER THERAPEUTICS IN THE GLOBAL MARKETWHAT IS CANCER?Table 29: THERAPEUTICS FOR PROSTATE CANCER TREATMENTDRUGS APPROVED FOR PROSTATE CANCERLUPRON (LEUPROLIDE ACETATE)TAXOTERE (DOCETAXEL)JEVTANA (CABAZITAXEL)ZYTIGA (ABIRATERONE ACETATE)PROVENGE (SIPULEUCEL-T)XGEVA (DENOSUMAB)Table 31: COMMON DRUGS FOR TREATMENT OF PROSTATE CANCERAVODART (DUTASTERIDE)Table 30: APPROVED FDA PROSTATE CANCER DRUGSDRUG DESCRIPTIONSCASODEX (BICALUTAMIDE)Clinical PharmacologyClinical StudiesFigure 1: STRUCTURE OF CASODEXZOLADEX (GOSERELIN ACETATE)Clinical PharmacologyClinical Studies
  • 7. Post-Marketing StudiesFigure 2: CHEMICAL STRUCTURE OF ZOLADEXELIGARD (LEUPROLIDE)Clinical PharmacologyClinical StudiesPost-Marketing StudiesFigure 3: CHEMICAL STRUCTURE OF ELIGARDNILANDRON (NILUTAMIDE)Clinical PharmacologyClinical StudiesPost-Marketing StudiesFigure 4: CHEMICAL STRUCTURE OF NILANDRONFLUTAMIDEClinical PharmacologyClinical StudiesPost Marketing StudiesFigure 5: CHEMICAL STRUCTURE OF FLUTAMIDETRIPTORELIN (TRELSTAR)Clinical PharmacologyClinical TrialsPost-Marketing StudiesFigure 6: CHEMICAL STRUCTURE OF TRELSTARESTRAMUSTINE (EMCYT)Clinical PharmacologyFigure 7: CHEMICAL STRUCTURE OF ESTRAMUSTINEFIRMAGON (DEGARELIX ACETATE)Clinical PharmacologyClinical StudiesFigure 8: CHEMICAL STRUCTURE OF FIRMAGONTAXOTERE (DOCETAXEL)Clinical PharmacologyClinical StudiesPost-Marketing StudiesFigure 9: CHEMICAL STRUCTURE OF DOCETAXELJEVTANA (CABAZITAXEL)Clinical PharmacologyClinical StudiesFigure 10: CHEMICAL STRUCTURE OF JEVTANAMITOXANTRONE (NOVANTRONE)VINORELBINE (NAVELBINE)ZYTIGA (ABIRATERONE ACETATE)Clinical Pharmacology
  • 8. Clinical StudiesFigure 11: CHEMICAL STRUCTURE OF ZYTIGAPROVENGE (SIPULEUCEL-T)Clinical PharmacologyClinical StudiesOTHER THERAPEUTIC AGENTSTable 32: THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICALDEVELOPMENTChapter - 8: GLOBAL BURDEN OF CANCERGLOBAL PROSTATE CANCER STATISTICSPROSTATE CANCER MORTALITYTable 35: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZEDMORTALITY RATES PER 100,000 MEN, 2008Figure 14: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZEDMORTALITY RATES PER 100,000 MEN, 2008Table 34: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008Figure 13: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008PROSTATE CANCER BURDEN GLOBALLYTable 36: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030Figure 15: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030PROSTATE CANCER IN THE U.S.PROSTATE CANCER MORTALITY RATES IN THE U.S.Table 41: MORTALITY RATES BY RACE IN THE U.S., 2005-2009PROSTATE CANCER AND AFRICAN AMERICAN MENTable 42: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSISFOR MALES OF ALL RACES, 2002-2008Table 43: RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTSSURVIVAL RATES BY STAGETable 44: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSISTable 37: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011Figure 16: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011Table 38: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030Figure 17: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030Table 39: INCIDENCE RATES BY RACE IN THE U.S., 2005-2009Table 40: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030Figure 18: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030PROSTATE CANCER AND CANADATable 45: ESTIMATED PROSTATE CANCER IN CANADA, 2012PROSTATE CANCER AND EUROPEPROSTATE CANCER AND UNITED KINGDOMTable 47: PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010Figure 20: PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010
  • 9. Table 46: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008Figure 19: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008PROSTATE CANCER IN ASIAOTHER NATIONSJAMAICAAUSTRALIACONCLUSIONSTable 33: GLOBAL CANCER INCIDENCE ESTIMATES, 2008Figure 12: GLOBAL CANCER INCIDENCE ESTIMATES, 2008Chapter - 9: PROSTATE CANCER AND DIAGNOSTIC MARKETSCREENING TESTSPSA TESTING: YES OR NO CONTROVERSYPROSTATE CANCER MARKET SIZEPROSTATE CANCER SCREENING MARKETPSA Test and MarketTable 49: GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017Figure 21: GLOBAL PSA TEST SALES AND FORECAST, 2010 - 2017Table 50: U.S. PSA TEST SALES AND FORECAST, THROUGH 2017Figure 22: U.S. PSA TEST SALES AND FORECAST, 2011 - 2017Table 51: EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017Figure 23: EUROPEAN PSA TEST SALES AND FORECAST, 2011 - 2017Table 52: CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017Figure 24: CANADIAN PSA TEST SALES AND FORECAST, 2011 - 2017Table 53: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017Figure 25: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010 - 2017DRE MARKETTable 54: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH2017Figure 26: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017Table 55: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017Figure 27: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017Table 56: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THEWORLD (EXCLUDING THE U.S.), THROUGH 2017Figure 28: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THEWORLD (EXCLUDING THE U.S.), 2010 - 2017MARKET FOR PROSTATE BIOPSYPSA and DRE Manufacturers and MarketTable 62: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKETSHARE, 2012Table 57: GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017
  • 10. Figure 29: GLOBAL COST OF PROSTATE BIOPSIES, 2010 - 2017Table 58: U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017Figure 30: U.S. COST OF PROSTATE BIOPSIES, 2010 - 2017Table 59: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THEU.S.), THROUGH 2017Figure 31: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THEU.S.), 2010 - 2017Table 60: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION,THROUGH 2017Figure 32: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010 -2017Table 61: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH2017Figure 33: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010 - 2017NEW TESTS ON THE HORIZONMyriad GeneticsProstate Health IndexAnalizaDxMDxHealth and PLUS DiagnosticsOpko HealthTable 63: LIST OF AVAILABLE PROSTATE NOMOGRAMSGenomic HealthMDxHealthCaris Life SciencesGen-ProbeTable 48: TYPE OF DIAGNOSTIC TESTSPROSTATE CANCER DIAGNOSTIC IMAGING MARKETTable 64: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017Figure 34: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010 - 2017Table 65: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICESMARKET SHARE, 2012Chapter - 10: THE PROSTATE TREATMENT MARKETTREATMENT PLAN FOR PROSTATE CANCERPROSTATE CANCER THERAPIES: THREE LEADING PROSTATE CANCER THERAPIESTable 66: COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012PROSTATE CANCER SURGERY AND RADIOTHERAPY MARKETTable 67: SURGICAL DEVICE COMPANIES: KEY PLAYERSTable 68: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST,THROUGH 2017Figure 35: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010- 2017RADIOTHERAPY MARKET
  • 11. Table 69: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST ANDSALES, 2010 - 2017Figure 36: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST ANDSALES, 2010 - 2017PROSTATE CANCER SURGICAL DEVICE MARKETBRACHYTHERAPY MARKETTable 70: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017Figure 37: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010 - 2017PROSTATECTOMY MARKETTable 71: GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017Figure 38: GLOBAL INCIDENCE OF PROSTATE CANCER, 2008 - 2017Table 72: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 - 2017Figure 39: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 -2017Table 73: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST,THROUGH 2017Figure 40: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009 -2017Table 74: GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR,2009 - 2017Figure 41: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017Table 75: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,THROUGH 2017Figure 42: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,2009 - 2017Table 76: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR,THROUGH 2017Figure 43: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009 -2017Table 77: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST,THROUGH 2017Figure 44: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009 -2017U.S. UROLOGICAL MARKETU.S. Market for Brachytherapy DevicesTable 79: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017Figure 46: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010 - 2017Table 80: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017Figure 47: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017Table 81: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH2017
  • 12. Figure 48: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017Table 82: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -2017Figure 49: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -2017Table 83: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017Figure 50: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017Table 78: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017Figure 45: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009 - 2017PROSTATE CANCER DEVICE MARKET IN ASIA AND LATIN AMERICAMARKET: PROSTATE CANCER DRUGSGLOBAL ONCOLOGY THERAPEUTICS MARKETNew Approaches to Treat Prostate CancerTable 84: GLOBAL CANCER MARKET, THROUGH 2017Figure 51: GLOBAL CANCER MARKET, 2010 - 2017CYTOTOXIC THERAPIES MARKETTable 85: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017Table 86: CYTOTOXIC THERAPIES MARKET INDICATIONSTable 87: EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGSTable 88: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017Figure 52: U.S. CYTOTHERAPEUTICS MARKET, 2010 - 2017Table 89: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017Figure 53: EUROPEAN CYTOTHERAPEUTICS MARKET, 2010 - 2017Table 90: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017Figure 54: JAPANESE CYTOTHERAPEUTICS MARKET, 2010 - 2017Table 91: MAJOR CYTOTOXIC BRANDS SALES, 2011PROSTATE CANCER INCIDENCE AND IMPACT ON MARKETProstate Cancer Market SizeTable 92: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH2017Figure 55: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010 - 2017Cost of Prostate Cancer Therapy, Care and ManagementCURRENT PROSTATE CANCER THERAPEUTICSTable 93: PROSTATE CANCER DRUG MARKET, THROUGH 2017Figure 56: PROSTATE CANCER DRUG MARKET, 2010 - 2017Table 94: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH2017Figure 57: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010 - 2017GENERIC PROSTATE CANCER DRUGSNEWER THERAPIES ON THE MARKETRECENT DRUG APPROVALS AND MARKET
  • 13. Table 96: NEW DRUGS AND SALES FORECAST, 2017Table 95: U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIESPROSTATE CANCER: THERAPEUTIC DRUGS LANDSCAPEMARKET FOR CHEMOTHERAPYTable 98: GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGSTable 99: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES ANDFORECAST, THROUGH 2017Figure 58: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES ANDFORECAST, 2010 - 2017MARKET FOR CHEMOTHERAPY DRUGS FOR PROSTATE CANCERTaxotere/DocetaxelTable 100: KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES ANDFORECAST, 2010 - 2012Cabazitaxel/JevtanaMitoxantrone (Novantrone)Vinorelbine (Navelbine)Estramustine (Emcyt)MARKET FOR HORMONE THERAPYTable 101: GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGSTable 102: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST,THROUGH 2017Figure 59: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010 -2017Table 103: GENERICS: SALES AND FORECAST, THROUGH 2017HORMONE THERAPY DRUGSCasodex or BicalutamideZytiga/AbirateroneTable 105: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012Figure 61: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012Table 106: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017Figure 62: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017Xtandi or EnzalutamideFlutamideTable 107: GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010NilutamideTriptorelinTable 108: GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010Leuprolide AcetateTable 109: GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010ZoladexTable 110: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017Figure 63: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017
  • 14. Degarelix AcetateMARKET FOR IMMUNOTHERAPYProvengeTable 112: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017Figure 65: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017Provenge and Future GrowthProvenge and Abiraterone CompetitionTable 111: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,THROUGH 2017Figure 64: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,2010 - 2017PROSTATE CANCER CARE MARKETTable 113: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017Figure 66: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017Table 114: PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017Figure 67: PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017Table 115: U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017Figure 68: U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017Table 116: PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017Figure 69: PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017Table 97: GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010 - 2012CONCLUSIONSTable 117: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH2017Figure 70: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017Chapter - 11: EMERGING PROSTATE CANCER DRUGSCABOZANTINIBXGEVACUSTIRSENTASQUINIMODSPRYCELTAK-700PROSTVACALPHARADINAVODARTDCVAX-PROSTATECONCLUSIONSTable 118: EMERGING PRODUCTS FOR PROSTATE CANCERChapter - 12: PROSTATE CANCER PATENTSPROSTATE CANCER DRUG PATENTS EXPIRYNEW PATENT APPLICATIONSCZ BioMed Corp.
  • 15. Adamis PharmaceuticalsAntisense TherapeuticsTable 121: EXPIRY OF PATENTS ON MAJOR BRANDSTable 122: LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONSTable 119: PROSTATE CANCER PATENT TRENDS, 2002-2011Table 120: PATENTS BY TREATMENT CATEGORY, 2002 - 2011Chapter - 13: RESEARCH AND INNOVATIONS IN TECHNOLOGYNEW THERAPEUTIC DEVELOPMENTSONCOGENEXMEDIVATIONSPECTRUM PHARMACEUTICALSNEW DEVELOPMENTS IN DIAGNOSTIC TESTING FOR PSAGENOMIC HEALTHNEW MRI TECHNOLOGYHIGH-INTENSITY FOCUSED ULTRASOUNDCONCLUSIONSChapter - 14: SELECTED COMPANY PROFILESABBOTT LABORATORIESACTIVE BIOTECH ABALGETAAMGENASTELLAS PHARMA USASTRAZENECAATRIX LABORATORIESBAVARIAN NORDIC A/SBAYER HEALTHCARE PHARMACEUTICALSBRISTOL-MYERS SQUIBBC.R. BARDCZ BIOMED CORP.DENDREON CORP.DIAGNOCUREEXELIXISGE HEALTHCAREGENOMIC HEALTHGLAXOSMITHKLINEHOLOGICINTUITIVE SURGICALJOHNSON & JOHNSONMEDIVATIONMILLENNIUM PHARMACEUTICALSMYRIAD GENETICSNORTHWEST BIOTHERAPEUTICS
  • 16. ONCOGENEXOPKO HEALTHPFIZERSANOFISIEMENS AGSPECTRUM PHARMACEUTICALSVARIAN MEDICAL SYSTEMSChapter - 15: REFERENCESLIST OF TABLESSummary Table: GLOBAL PROSTATE CANCER MARKET, THROUGH 2017Table 1: U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008Table 2: GROWTH FACTORS IMPLICATED IN PROSTATE CANCERTable 3: PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCITable 4: IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCERTable 5: MUTATED GENES AND ABNORMAL PROTEIN EXPRESSIONTable 6: WHY PSA TESTING?Table 7: PROSTATE CANCER: MAJOR POINTSTable 8: ACS RECOMMENDATIONS FOR THE EARLY DETECTION OF CANCER INAVERAGE-RISK, ASYMPTOMATIC INDIVIDUALSTable 9: PSA TEST: WHY AND WHEN?Table 10: AGE-SPECIFIC REFERENCE RANGES FOR SERUM PSATable 11: OTHER CAUSES OF CHANGES IN PSA LEVELTable 12: IMPROVEMENTS TO THE PSA TESTTable 13: PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGYTable 14: PROSTATE CANCER TESTSTable 15: TREATMENT OPTIONS FOR PROSTATE CANCERTable 16: FACTORS FOR PROSTATE CANCER TREATMENT PLANNINGTable 17: GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENTTable 18: TYPES OF SURGERYTable 19: ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMYTable 20: ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHYTHERAPYTable 21: ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPYTable 22: ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPYTable 23: ADVANTAGES AND DISADVANTAGES OF ULTRASOUNDTable 24: HORMONE THERAPYTable 25: STAGE I PROSTATE CANCERTable 26: STAGE II PROSTATE CANCERTable 27: STAGE III PROSTATE CANCERTable 28: STAGE IV PROSTATE CANCERTable 29: THERAPEUTICS FOR PROSTATE CANCER TREATMENTTable 30: APPROVED FDA PROSTATE CANCER DRUGSTable 31: COMMON DRUGS FOR TREATMENT OF PROSTATE CANCER
  • 17. Table 32: THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICALDEVELOPMENTTable 33: GLOBAL CANCER INCIDENCE ESTIMATES, 2008Table 34: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008Table 35: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZEDMORTALITY RATES PER 100,000 MEN, 2008Table 36: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030Table 37: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011Table 38: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030Table 39: INCIDENCE RATES BY RACE IN THE U.S., 2005-2009Table 40: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030Table 41: MORTALITY RATES BY RACE IN THE U.S., 2005-2009Table 42: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSISFOR MALES OF ALL RACES, 2002-2008Table 43: RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTSTable 44: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSISTable 45: ESTIMATED PROSTATE CANCER IN CANADA, 2012Table 46: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008Table 47: PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010Table 48: TYPE OF DIAGNOSTIC TESTSTable 49: GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017Table 50: U.S. PSA TEST SALES AND FORECAST, THROUGH 2017Table 51: EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017Table 52: CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017Table 53: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017Table 54: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH2017Table 55: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017Table 56: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THEWORLD (EXCLUDING THE U.S.), THROUGH 2017Table 57: GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017Table 58: U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017Table 59: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THEU.S.), THROUGH 2017Table 60: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION,THROUGH 2017Table 61: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH2017Table 62: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKETSHARE, 2012Table 63: LIST OF AVAILABLE PROSTATE NOMOGRAMS
  • 18. Table 64: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017Table 65: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICESMARKET SHARE, 2012Table 66: COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012Table 67: SURGICAL DEVICE COMPANIES: KEY PLAYERSTable 68: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST,THROUGH 2017Table 69: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST ANDSALES, 2010 - 2017Table 70: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017Table 71: GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017Table 72: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 - 2017Table 73: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST,THROUGH 2017Table 74: GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR,2009 - 2017Table 75: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,THROUGH 2017Table 76: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR,THROUGH 2017Table 77: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST,THROUGH 2017Table 78: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017Table 79: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017Table 80: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017Table 81: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH2017Table 82: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -2017Table 83: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017Table 84: GLOBAL CANCER MARKET, THROUGH 2017Table 85: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017Table 86: CYTOTOXIC THERAPIES MARKET INDICATIONSTable 87: EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGSTable 88: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017Table 89: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017Table 90: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017Table 91: MAJOR CYTOTOXIC BRANDS SALES, 2011Table 92: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH2017Table 93: PROSTATE CANCER DRUG MARKET, THROUGH 2017Table 94: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH
  • 19. 2017Table 95: U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIESTable 96: NEW DRUGS AND SALES FORECAST, 2017Table 97: GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010 - 2012Table 98: GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGSTable 99: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES ANDFORECAST, THROUGH 2017Table 100: KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES ANDFORECAST, 2010 - 2012Table 101: GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGSTable 102: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST,THROUGH 2017Table 103: GENERICS: SALES AND FORECAST, THROUGH 2017Table 104: CASODEX SALES AND FORECAST, THROUGH 2017Table 105: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012Table 106: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017Table 107: GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010Table 108: GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010Table 109: GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010Table 110: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017Table 111: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,THROUGH 2017Table 112: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017Table 113: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017Table 114: PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017Table 115: U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017Table 116: PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017Table 117: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH2017Table 118: EMERGING PRODUCTS FOR PROSTATE CANCERTable 119: PROSTATE CANCER PATENT TRENDS, 2002-2011Table 120: PATENTS BY TREATMENT CATEGORY, 2002 - 2011Table 121: EXPIRY OF PATENTS ON MAJOR BRANDSTable 122: LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONSLIST OF FIGURESSummary Figure: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017Figure SAMPLE FIGURE: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017Figure 1: STRUCTURE OF CASODEXFigure 2: CHEMICAL STRUCTURE OF ZOLADEXFigure 3: CHEMICAL STRUCTURE OF ELIGARDFigure 4: CHEMICAL STRUCTURE OF NILANDRONFigure 5: CHEMICAL STRUCTURE OF FLUTAMIDE
  • 20. Figure 6: CHEMICAL STRUCTURE OF TRELSTARFigure 7: CHEMICAL STRUCTURE OF ESTRAMUSTINEFigure 8: CHEMICAL STRUCTURE OF FIRMAGONFigure 9: CHEMICAL STRUCTURE OF DOCETAXELFigure 10: CHEMICAL STRUCTURE OF JEVTANAFigure 11: CHEMICAL STRUCTURE OF ZYTIGAFigure 12: GLOBAL CANCER INCIDENCE ESTIMATES, 2008Figure 13: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008Figure 14: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZEDMORTALITY RATES PER 100,000 MEN, 2008Figure 15: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030Figure 16: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011Figure 17: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030Figure 18: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030Figure 19: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008Figure 20: PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010Figure 21: GLOBAL PSA TEST SALES AND FORECAST, 2010 - 2017Figure 22: U.S. PSA TEST SALES AND FORECAST, 2011 - 2017Figure 23: EUROPEAN PSA TEST SALES AND FORECAST, 2011 - 2017Figure 24: CANADIAN PSA TEST SALES AND FORECAST, 2011 - 2017Figure 25: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010 - 2017Figure 26: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017Figure 27: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017Figure 28: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THEWORLD (EXCLUDING THE U.S.), 2010 - 2017Figure 29: GLOBAL COST OF PROSTATE BIOPSIES, 2010 - 2017Figure 30: U.S. COST OF PROSTATE BIOPSIES, 2010 - 2017Figure 31: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THEU.S.), 2010 - 2017Figure 32: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010 -2017Figure 33: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010 - 2017Figure 34: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010 - 2017Figure 35: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010- 2017Figure 36: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST ANDSALES, 2010 - 2017Figure 37: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010 - 2017Figure 38: GLOBAL INCIDENCE OF PROSTATE CANCER, 2008 - 2017Figure 39: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 -2017
  • 21. Figure 40: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009 -2017Figure 41: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017Figure 42: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,2009 - 2017Figure 43: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009 -2017Figure 44: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009 -2017Figure 45: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009 - 2017Figure 46: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010 - 2017Figure 47: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017Figure 48: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017Figure 49: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -2017Figure 50: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017Figure 51: GLOBAL CANCER MARKET, 2010 - 2017Figure 52: U.S. CYTOTHERAPEUTICS MARKET, 2010 - 2017Figure 53: EUROPEAN CYTOTHERAPEUTICS MARKET, 2010 - 2017Figure 54: JAPANESE CYTOTHERAPEUTICS MARKET, 2010 - 2017Figure 55: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010 - 2017Figure 56: PROSTATE CANCER DRUG MARKET, 2010 - 2017Figure 57: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010 - 2017Figure 58: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES ANDFORECAST, 2010 - 2017Figure 59: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010 -2017Figure 60: CASODEX SALES AND FORECAST, 2011-2017Figure 61: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012Figure 62: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017Figure 63: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017Figure 64: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,2010 - 2017Figure 65: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017Figure 66: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017Figure 67: PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017Figure 68: U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017Figure 69: PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017Figure 70: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017
  • 22. Contact: sales@reportsandreports.com for more information.